Breast cancer patients receiving aromatase inhibitors as antihormone therapy are at major risk of cardiovascular disease. Previous observations suggest that, since estrogen biosynthesis is regulated by aromatase and aldosterone biosynthesis is modulated by aldosterone synthase, a dual inhibitor could have anticancer efficacy while reducing cardiovascular risks in breast cancer patients.

Subcommisural organ (SCO)-spondin is a brain-specific glycoprotein essential for neurogenesis with a high impact on neuronal development; thus, reduction in the production of SCO-spondin may lead to a lack of regeneration in neurological disorders.

Nextpoint Therapeutics Inc. has received FDA clearance of its IND application for NPX-887, a fully human monoclonal antibody targeting HHLA2 (B7-H7), a novel immune checkpoint and tumor target antigen highly expressed in many cancers independently of PD-L1.